OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2025
Summary
Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which codes for the CFTR protein. As a multisystem condition, CF patients show great heterogeneity in presenting clinical symptoms. CF mainly affects the respiratory and gastrointestinal tracts. Three classes of drugs have been used to for treatment in CF patie
Read More
- 1.1 List of Tables
- Table 1: Cystic Fibrosis: Key Metrics in the Seven Major Pharmaceutical Markets 9
- Table 2: Onset of CF by Approximate Age 18
- Table 3: Classification and Criteria of the CFTR Gene Mutations in CF 20
- Table 4: Symptoms of CF 22
- Table 5: Risk Factors and Comorbidities of CF 26
- Table 6: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of CF (Based on
- Registry Data) 30
- Table 7: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of CF (Based on Registry Data) 31
- T
Read More
- 1 Table of Contents
- 1 Table of Contents 2
- 1.1 List of Tables 6
- 1.2 List of Figures 7
- 2 Cystic Fibrosis: Executive Summary 9
- 2.1 CF Transmembrane Conductance Regulator Modulators Expected to Drive Substantial Growth in the Cystic Fibrosis Market from 2015-2025 9
- 2.2 Licensing Activity and the Formation of New Partnerships Will Steer Small Companies to Continue Research of Novel Compounds 11
- 2.3 Marketed and Pipeline CF Transmembrane Conductance Regulator Modulators Will Provide Appropriate Treatm
Read More